Physician profile
Stuart A Kravitz
NPI 1235119330
$2,079.16
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $231 · 2021: $50.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $377.52 | 2019 | |
| Glaxosmithkline, LLC. | $332.03 | 2019-2021 | |
| Optinose US, INC. | $223.73 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $219.90 | 2019-2020 | |
| Shire North American Group INC | $157.82 | 2019 | |
| Alk-Abello, INC | $142.47 | 2019 | |
| Genentech USA, INC. | $135.71 | 2020 | |
| Horizon Therapeutics Plc | $125.93 | 2019 | |
| Csl Behring | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $86.62 | 2019 | |
| Kaleo, INC. | $73.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.67 | 2019 | |
| Circassia INC. | $14.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Kravitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.